Last updated 6 days ago
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
606 patients around the world
Available in Argentina, Mexico, Puerto Rico, United States
Eli Lilly and Company
11Research sites
606Patients around the world
This study is for people with
Chronic obstructive pulmonary disease
Copd
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria.Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years.Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (<) 70 percent (%).Modified Medical Research Council Dyspnea Scale (mMRC-DS) grade ≥2.Exacerbation history of ≥2 moderate or ≥1 severe exacerbations within the year prior to inclusion.Background double therapy [long-acting β₂-agonists (LABA) + long-acting muscarinic antagonists (LAMA)] or triple therapy [inhaled corticosteroids (ICS) + LABA + LAMA)] for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to screening.
- Have a known pre-existing, clinically important lung condition other than COPD.Have a current or recent acute, active infection before screening and up to randomization.
Sites
Centro Médico Viamonte SRL - CABA, Buenos Aires
Fundación Respirar
Consultorios Médicos Dr. Isaac Scherbovsky - Mendoza
Instituto Médico Río Cuarto
Fundación Centro de Salud e Investigaciones Médicas (CESIM)
Consultorios Médicos del Buen Ayre
Köhler & Milstein Research
Scientia Investigacion Clinica S.C.
Unidad Medica para la Salud Integral (UMSI)
Medimanage Research
StudyRENEW-COPD
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Copd
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07759245
